Bayer | Ophthalmology’s Post

Identifying patients who will derive long-term benefit from anti-VEGF treatment is a difficult, but very important, treatment decision. Share with us in the comments the steps you take in your clinic to investigate if treatment cessation is best for your patient.    Listen to the new episode of “A Chat with Anat” on Spotify (https://bit.ly/3ZhLrLL) or Apple (https://bit.ly/4f1s9Aa), where Professor Anat Loewenstein is joined by fellow Vision Academy and Barometer member Professor David Wong to discuss treatment futility and treatment success in the context of suspending anti-VEGF treatment of nAMD. Click to download the Vision Academy flowchart (https://bit.ly/48Yhwwy) discussed in the podcast, in the Viewpoint and slide deck (https://bit.ly/3AUj3Hv).    Explore more episodes of “A Chat with Anat” on Spotify or Apple, to hear Anat discuss other key topics with internationally renowned experts on how to enhance care and optimize treatment for patients with retinal disease.    #ExpandKnowledge #Awareness #VisionAcademy

  • Graphic for the “A Chat with Anat” podcast, the ophthalmologist’s podcast hosted by Professor Anat Loewenstein. The graphic features the podcast title “Treatment futility and success in the context of suspending treatment”, with special guest Professor David Wong.

To view or add a comment, sign in

Explore topics